PRFXNasdaqPharmaceutical PreparationsUS GAAP · USD

PRF Technologies Ltd.

PRF Technologies Ltd. is a U.S.-listed company with two operating lines: a pharmaceutical development business focused on reformulating established therapeutics, and a software business built around its DeepSolar platform for AI-driven energy optimization. The company’s technology footprint includes the GridFeed and DeepSolar Predict offerings, which are used in renewable-energy forecasting, trading support, and performance optimization, alongside pharmaceutical programs using an extended-release drug-delivery system.

Revenue0.0m USD
Operating profit (EBIT)-5.1m USD
+65.1 %y/y
EBIT margin-30,129.4%
Net income-5.0m USD
+65.6 %y/y
Free cash flow-4.0m USD
+68.7 %y/y

Fiscal year 2025 · change from previous year

Development 2020–2025

-15-10-505m USD2020: EBIT -1.7 m USD20202021: EBIT -7.2 m USD20212022: EBIT -8.9 m USD20222023: 0.00 m USD2023: EBIT -9.6 m USD20232024: 0.00 m USD2024: EBIT -15 m USD20242025: 0.02 m USD2025: EBIT -5.1 m USD20250.02-5.1
RevenueOperating profit (EBIT)

Business

Share of revenue
Pharmaceutical development50 %

Programs to reformulate established therapeutics using proprietary drug-delivery systems.

Energy analytics software30 %

AI-based software for forecasting, monitoring, and optimizing energy use and production.

Energy trading decision support20 %

GridFeed tools for market participation, trading support, and revenue optimization.

Customers

PRF serves two very different customer groups: healthcare stakeholders interested in reformulated therapeutics and extended-release drug delivery, and renewable-energy participants needing forecasting and market decision tools. On the energy side, the company targets solar asset owners, operators, investors, traders, balancing responsible parties, and other market participants that need better visibility into production and price dynamics.

Solar asset owners and operators

Buy forecasting, analytics, and optimization tools to improve solar performance and reduce imbalance costs.

Energy traders and market participants

Use GridFeed for day-ahead and intraday trading decisions and revenue optimization.

Renewable-energy investors and advisors

Use DeepSolar analytics for technical due diligence, performance review, and risk assessment.

Healthcare and pharmaceutical partners

Support development and potential commercialization of reformulated therapeutic candidates.

Strategy

PRF is building a dual-track business that combines pharmaceutical reformulation with AI-enabled energy software, giving it exposure to both life sciences and renewable-energy workflows. Near term, the company is focused on advancing clinical development while commercializing DeepSolar through customer meetings, partnerships, and broader deployment of GridFeed in energy trading and optimization.

Advance OcuRing™-K and other healthcare programsShort term

Clinical progress is needed to create optionality in the pharmaceutical pipeline and support long-term value creation.

Commercialize GridFeed in EuropeShort term

European energy trading is a concrete target market where the company can win early adopters for its AI tools.

Broaden DeepSolar from analytics into monetizable trading supportMedium term

Moving from forecasting to trading and revenue optimization expands the platform's value proposition and addressable use cases.

Geography

The company is U.S.-listed, but its reported operating footprint is international, with a disclosed base in Tel Aviv, Israel and commercial activity aimed at European energy markets. Its DeepSolar business is being presented to market participants in Europe, while the pharmaceutical programs are described through U.S.-based clinical development and reporting structures.

Risks

PRF faces the execution risks of a diversified early-stage company: clinical-development uncertainty in pharmaceuticals and adoption risk in a nascent software platform. It also has listing and financing risk, since management has disclosed the importance of meeting Nasdaq continued-listing standards and the business depends on external funding and partner traction.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Funding and dilution risk1Nasdaq continued listing compliance2Clinical development failure3Commercial adoption risk for DeepSolar4
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Funding and dilution riskImpact: HighLikelihood: High

    Early-stage development and commercialization typically require ongoing external capital.

    Exposure: Equity issuance and warrant overhang

  2. Nasdaq continued listing complianceImpact: HighLikelihood: Medium

    The company disclosed risk of delisting if it fails minimum bid price, equity, or market value requirements.

    Exposure: Ordinary shares and capital-market access

  3. Clinical development failureImpact: HighLikelihood: Medium

    Pharmaceutical candidates depend on trial execution and regulatory outcomes that can be delayed or negative.

    Exposure: OcuRing™-K and reformulation pipeline

  4. Commercial adoption risk for DeepSolarImpact: MediumLikelihood: High

    The platform is still being introduced to customers and partners, so revenue conversion depends on market acceptance.

    Exposure: GridFeed and AI energy software

Accounting

Judgemental items
Deferred tax assets and valuation allowance

The company noted changes in valuation allowance on tax losses and other deferred tax assets.

Impact: Can materially change reported tax expense and equity

Uncertain tax positions

Management must estimate interest and penalties tied to unrecognized tax positions.

Impact: Affects tax expense and contingency disclosures

Diluted loss per share

Options, warrants, and prefunded warrants can affect the denominator when dilutive.

Impact: Affects per-share comparability and dilution analysis

Publicly listed companies with a comparable business focus.

Last updated: 28/09/2026